BACKGROUND AND OBJECTIVES: To assess the efficacy and the toxic profile of gemcitabine, a novel pyrimidine antimetabolite active against several solid tumors, we carried out a study in heavily pretreated Hodgkin's disease (HD) patients. DESIGN AND METHODS: From May 1997 to January 1999, 14 pretreated patients (10 relapsed and 4 refractory to previous treatments) were enrolled in a phase II trial and treated with gemcitabine. The drug was given on days 1, 8 and 15 of a 28-day schedule at a dose of 1,200 mg/m2 intravenously for a total of 6 cycles. RESULTS: Two (14%) patients achieved complete remission (CR) and 4 (29%) had partial responses (PR), giving an overall response rate of 43%. In the relapsed subset there was an overall response rate of 50% with 2 CR and 3 PR. Among the refractory patients there was only 1 PR (25%). Both patients who had relapsed after autologous bone marrow transplant achieved a response (1 CR and 1 PR). No major toxic effects were recorded. INTERPRETATION AND CONCLUSIONS: These data suggest that gemcitabine is an effective drug with a low toxicity profile in patients with heavily pretreated HD. Further trials using gemcitabine in combination with other conventional drugs are needed.
BACKGROUND AND OBJECTIVES: To assess the efficacy and the toxic profile of gemcitabine, a novel pyrimidine antimetabolite active against several solid tumors, we carried out a study in heavily pretreated Hodgkin's disease (HD) patients. DESIGN AND METHODS: From May 1997 to January 1999, 14 pretreated patients (10 relapsed and 4 refractory to previous treatments) were enrolled in a phase II trial and treated with gemcitabine. The drug was given on days 1, 8 and 15 of a 28-day schedule at a dose of 1,200 mg/m2 intravenously for a total of 6 cycles. RESULTS: Two (14%) patients achieved complete remission (CR) and 4 (29%) had partial responses (PR), giving an overall response rate of 43%. In the relapsed subset there was an overall response rate of 50% with 2 CR and 3 PR. Among the refractory patients there was only 1 PR (25%). Both patients who had relapsed after autologous bone marrow transplant achieved a response (1 CR and 1 PR). No major toxic effects were recorded. INTERPRETATION AND CONCLUSIONS: These data suggest that gemcitabine is an effective drug with a low toxicity profile in patients with heavily pretreated HD. Further trials using gemcitabine in combination with other conventional drugs are needed.
Authors: Jessica A Shafer; Conrad R Cruz; Ann M Leen; Stephanie Ku; An Lu; Alexandra Rousseau; Helen E Heslop; Cliona M Rooney; Catherine M Bollard; Aaron E Foster Journal: Leuk Lymphoma Date: 2010-05
Authors: David J Straus; Jeffrey L Johnson; Ann S LaCasce; Nancy L Bartlett; Lale Kostakoglu; Eric D Hsi; Heiko Schöder; Nathan C Hall; Sin-Ho Jung; George P Canellos; Lawrence H Schwartz; Ronald W Takvorian; Malik E Juweid; Bruce D Cheson Journal: Blood Date: 2011-02-25 Impact factor: 22.113
Authors: Sally Arai; Renee Letsinger; Ruby M Wong; Laura J Johnston; Ginna G Laport; Robert Lowsky; David B Miklos; Judith A Shizuru; Wen-Kai Weng; Philip W Lavori; Karl G Blume; Robert S Negrin; Sandra J Horning Journal: Biol Blood Marrow Transplant Date: 2010-03-01 Impact factor: 5.742
Authors: Albert J van Hell; Adriana Haimovitz-Friedman; Zvi Fuks; William D Tap; Richard Kolesnick Journal: Cell Signal Date: 2017-02-24 Impact factor: 4.315
Authors: Peter D Cole; Cindy L Schwartz; Richard A Drachtman; Pedro A de Alarcon; Lu Chen; Tanya M Trippett Journal: J Clin Oncol Date: 2009-02-17 Impact factor: 44.544
Authors: J H Mendler; J Kelly; S Voci; D Marquis; L Rich; R M Rossi; S H Bernstein; C T Jordan; J Liesveld; R I Fisher; J W Friedberg Journal: Ann Oncol Date: 2008-05-25 Impact factor: 32.976
Authors: Ki Hyang Kim; Young Don Joo; Chang Hak Sohn; Ho Jin Shin; Joo Seop Chung; Goon Jae Cho; Sung Hoon Shin; Yang Soo Kim; Won Sik Lee Journal: Korean J Intern Med Date: 2009-03 Impact factor: 3.165